MGI Tech Ranked Among China's Top 100 Innovative Medical Device Companies for the Third Time and Announces New Sequencing Instrument Launch in September

On June 15, 2022, the “2022 Top 100 Future Healthcare Companies” list, jointly selected by VB100, VCBeat, and Eggshell Research Institute, was officially released.MGI Honored as One of the “Top 100 Future Healthcare Companies · Main List — China Innovative Medical Devices List”00Strong” and was awarded the “Top 100 Future Healthcare Companies · Pengcheng Award – Enterprise Leader of the Year.” 

Established in 2015, the Future Healthcare Top 100 is China’s first ranking list focused on innovative healthcare companies that are not publicly listed. It aims to identify Chinese innovators who truly represent the future of healthcare, uncover the core driving forces behind China’s future healthcare industry, and promote innovation and transformation within the health and medical sectors. Over the past seven years, the Future Healthcare Top 100 ranking system has been continuously enriched, gradually evolving into a global innovation healthcare ecosystem ranking that serves enterprises, investment institutions, hospitals, and industrial parks. It is currently the most watched annual selection in the life and health sector by both industry professionals and investors. 

“The 2022 Top 100 Future Healthcare Conference” was held entirely online, adopting “China’s Story” as its foundational perspective to convey the narrative of China’s own life sciences industry.6Month 15evening, “2022Future Healthcare 100Grand Launch of the “Power Rankings · Cloud Release Ceremony.” MGIOOMs. Jiang Hui attended the online live broadcast, delivering an acceptance speech as a representative of the outstanding listed companies and participating in interactive sessions. 

Mr. Bi Yuanfeng, COO of VCBeat, praised during the moderated interactive session,“MGI is a typical representative of China’s technology-innovation-driven enterprises and one of the few upstream companies in China that continuously conducts tool research and development in the life sciences field.”

In response, Ms. Jiang Hui stated, “MGI is honored to be listed on the “China Innovative Medical Device List” for the third time00strong'.MGI’s vision is “Innovative Intelligent Manufacturing Leading Life Sciences,” and it has consistently persisted in the independent research and development of “core tools for life sciences” over the years,Receiving this award aligns well with our ‘innovation’ DNA and demonstrates that we are heading in the right direction.”。

Regarding MGI’s future plans, Ms. Jiang Hui stated, “The most critical aspect of core life science tools lies in their application. First, in the research sector, MGI is launching a ‘three-pronged strategy’ this year, leveraging gene sequencers, laboratory automation, and new business initiatives to drive applications in large-scale population genomics, single-cell omics, and spatial-temporal omics, thereby empowering scientific breakthroughs with these new technologies. Second, in the clinical sector, we aim to empower humanity’s understanding of itself, as well as disease comprehension and prevention, through the application of gene sequencers and automated equipment in precise genetic testing for scenarios such as reproductive health, oncology, infectious diseases, and chronic diseases. Third, in emerging application areas, including disease control and agriculture, we hope to unlock greater possibilities in these fields through the deployment of life science tools.”

“We firmly believe in the power of innovation and are committed to the continuous research and development of new products.”, Ms. Jiang Hui concluded with a preview,“In September this year, MGI will launch a new gene sequencer. Please stay tuned and look forward to it.”